



Martine Piccart-Gebhart

Contact

Martine Piccart-Gebhart

Publications (5)

Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majaj S, Salgado R, Puztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. *Clin Cancer Res* 2021

Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. *Eur J Cancer* 2019; 118:169-177.

Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *J Clin Oncol* 2018:JCO1800440.

Powles R, Puztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncol* 2018; 4:e181564.

Lambertini M, de Azambuja E, Gelber R, Piccart-Gebhart M, Moreno-Aspitia A, Baselga J, Huober J, Tenglin R, Di Cosimo S, Azim H, Korde L, Schuehly U, Hilbers F, Guillaume S, Campbell C, Martel S, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. *Cancer* 2018; 125:307-316.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch